Trial · NCT02757326
Adverse events234
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 234
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Summary of Adverse events occurring in >10% of patients by System Organ Class and Preferred Term | Blood and lymphatic system disorders | 250 mg Phase 1b | 3 | 3 | 28 |
| other | Summary of Adverse events occurring in >10% of patients by System Organ Class and Preferred Term | Blood and lymphatic system disorders | 500 mg Phase 1b | 4 | 4 | 34 |
| other | Summary of Adverse events occurring in >10% of patients by System Organ Class and Preferred Term | Blood and lymphatic system disorders | 750 mg Phase 1b | 6 | 6 | 41 |
| other | Hypokalaemia | Metabolism and nutrition disorders | 250 mg Phase 1b | 1 | 3 | 1 |
| other | Hypokalaemia | Metabolism and nutrition disorders | 500 mg Phase 1b | 1 | 4 | 1 |
| other | Hypokalaemia | Metabolism and nutrition disorders | 750 mg Phase 1b | 3 | 6 | 3 |
| other | Hyponatraemia | Metabolism and nutrition disorders | 250 mg Phase 1b | 1 | 3 | 1 |
| other | Hyponatraemia | Metabolism and nutrition disorders | 500 mg Phase 1b | 2 | 4 | 2 |
| other | Hyponatraemia | Metabolism and nutrition disorders | 750 mg Phase 1b | 2 | 6 | 2 |
| other | Hypophosphataemia | Metabolism and nutrition disorders | 250 mg Phase 1b | 1 | 3 | 1 |
| other | Hypophosphataemia | Metabolism and nutrition disorders | 500 mg Phase 1b | 2 | 4 | 2 |
| other | Hypophosphataemia | Metabolism and nutrition disorders | 750 mg Phase 1b | 2 | 6 | 2 |
| other | Decreased appetite | Metabolism and nutrition disorders | 250 mg Phase 1b | 0 | 3 | 0 |
| other | Decreased appetite | Metabolism and nutrition disorders | 500 mg Phase 1b | 1 | 4 | 1 |
| other | Decreased appetite | Metabolism and nutrition disorders | 750 mg Phase 1b | 2 | 6 | 2 |
| other | Hypercalcaemia | Metabolism and nutrition disorders | 250 mg Phase 1b | 1 | 3 | 1 |
| other | Hypercalcaemia | Metabolism and nutrition disorders | 500 mg Phase 1b | 1 | 4 | 1 |
| other | Hypercalcaemia | Metabolism and nutrition disorders | 750 mg Phase 1b | 1 | 6 | 1 |
| other | Hypoalbuminaemia | Metabolism and nutrition disorders | 250 mg Phase 1b | 0 | 3 | 0 |
| other | Hypoalbuminaemia | Metabolism and nutrition disorders | 500 mg Phase 1b | 3 | 4 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02757326/events